PMID- 26909952
OWN - NLM
STAT- MEDLINE
DCOM- 20161114
LR  - 20181202
IS  - 1676-5680 (Electronic)
IS  - 1676-5680 (Linking)
VI  - 15
IP  - 1
DP  - 2016 Feb 5
TI  - Docetaxel enhances apoptosis and G2/M cell cycle arrest by suppressing 
      mitogen-activated protein kinase signaling in human renal clear cell carcinoma.
LID - 10.4238/gmr.15017321 [doi]
AB  - Tremendous efforts have been made in renal cell carcinoma (RCC) patients' 
      research; however, clinical findings in patients have been disappointing. The 
      aims of our study were to identify better or alternative therapeutic methods that 
      can reverse chemotherapy resistance and to enhance sensitivity to docetaxel 
      (DOX)-based chemotherapy drugs. We evaluated the anti-proliferative effect of DOX 
      against RCC cells. DOX was found to suppress proliferation of RCC cells under in 
      vitro and in vivo settings. Flow cytometric analysis revealed that DOX suppressed 
      cell growth by induction of both apoptosis and G2/M cell cycle arrest in a 
      dose-dependent manner. Various patterns of gene expression were observed by 
      cluster analysis. In addition, based on network analysis using the ingenuity 
      pathway analysis software, DOX was found to suppress phosphorylation of 
      extracellular signal-regulated kinase 1/2 and p38, suggesting that the 
      mitogen-activated protein kinase signaling pathway plays a vital role in the 
      anti-proliferative effect of DOX against RCC.
FAU - Han, T D
AU  - Han TD
AD  - Department of Urology, Beijing Friendship Hospital, Capital Medical University, 
      Beijing, China.
FAU - Shang, D H
AU  - Shang DH
AD  - Department of Urology, Beijing Friendship Hospital, Capital Medical University, 
      Beijing, China.
FAU - Tian, Y
AU  - Tian Y
AD  - Department of Urology, Beijing Friendship Hospital, Capital Medical University, 
      Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20160205
PL  - Brazil
TA  - Genet Mol Res
JT  - Genetics and molecular research : GMR
JID - 101169387
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - EC 2.7.11.24 (MAPK1 protein, human)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents, Phytogenic/*pharmacology
MH  - Apoptosis/drug effects
MH  - Carcinoma, Renal Cell/*drug therapy/genetics/metabolism/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Docetaxel
MH  - G2 Phase Cell Cycle Checkpoints/drug effects
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/genetics/metabolism/pathology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Mitogen-Activated Protein Kinase 1/*antagonists & inhibitors/genetics/metabolism
MH  - Mitogen-Activated Protein Kinase 3/*antagonists & inhibitors/genetics/metabolism
MH  - Signal Transduction/*drug effects
MH  - Taxoids/*pharmacology
MH  - Xenograft Model Antitumor Assays
MH  - p38 Mitogen-Activated Protein Kinases/*antagonists & 
      inhibitors/genetics/metabolism
EDAT- 2016/02/26 06:00
MHDA- 2016/11/15 06:00
CRDT- 2016/02/25 06:00
PHST- 2016/02/25 06:00 [entrez]
PHST- 2016/02/26 06:00 [pubmed]
PHST- 2016/11/15 06:00 [medline]
AID - gmr7321 [pii]
AID - 10.4238/gmr.15017321 [doi]
PST - epublish
SO  - Genet Mol Res. 2016 Feb 5;15(1). doi: 10.4238/gmr.15017321.